French Law Tackles Biologic Originator Tactics
Measures Form Part Of France’s Social Security Bill For 2020
Executive Summary
France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.
You may also be interested in...
Over-Regulation Is Damaging French Pharma Sector
Leem says “Inconsistent and unpredictable” policies are hitting industry’s competitiveness and limiting patients’ access to new medicines.
French Industry Pushes Back On Supply Penalties
Manufacturer obligations and sanctions set out by France’s government as part of efforts to deal with supply shortages have been condemned as counter-productive by local generics industry association Gemme.
France trials range of biosimilar incentives
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.